 Home > Medical News > Medical Research Articles > AI blood test shows that 90% of lung cancers at different stages can be detected

AI blood test shows that 90% of lung cancers at different stages can be detected

 Last Update: 2021-09-04
 Source: Internet
 Author: User

Tags

detect prostate cancer

low cost roofing

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Artificial intelligence (AI) blood testing technology was developed by Johns Hopkins Kimmel Cancer Center in nearly 800 samples of cancer patients and non-cancer patients, and found more than 90% of lung cancers

This detection method is called DELFI (for Early Intercepted DNA Fragment Evaluation), and it finds a unique pattern in the DNA fragments shed by cancer cells circulating in the blood, namely cell-free DNA (cfDNA)

Senior author Victor E.

The author pointed out that lung cancer is the most common cause of cancer deaths.

However, Velculescu explained that in the United States, less than 6% of people at risk of lung cancer have received the recommended low-dose computed tomography (LDCT) screening, although tens of thousands of deaths are expected to be avoided, while the world is screened.

DELFI technology uses blood tests to indirectly measure the way DNA is packaged in the nucleus by studying the size and quantity of circulating cfDNA from different regions of the genome

"In order to improve the sensitivity of early cancer detection, we have developed a genome-wide method to analyze cfDNA fragment profiles, called DELFI," the authors commented

In the reported study, researchers from Johns Hopkins University collaborated with researchers in Denmark and the Netherlands to perform cfDNA on blood samples of 365 individuals who participated in a 7-year study in Denmark called LUCAS for the first time.

The DELFI blood test uses artificial intelligence to detect the unique pattern of DNA fragments and normal DNA fragments in cancer cells to identify lung cancer

The researchers wrote: "In this study, we used this method to detect and identify lung cancer in a prospectively collected real cohort that included patients with malignant and benign lung nodules as well as non-cancer patients, including those Patients with other clinical symptoms

"The DNA fragmentation pattern provides a significant fingerprint for early cancer detection, and we believe this may be the basis for the widely used liquid biopsy detection for lung cancer patients," added co-author Dr.

The team concluded: "Through this effort, we have provided a framework for bringing non-invasive liquid biopsy into the clinic, combining cfDNA fragments with other markers and LDCT for lung cancer detection

An unprecedented national clinical trial, Delfi-l101, sponsored by Delfi Diagnostics, a subsidiary of Johns Hopkins University, is evaluating a Delfi-based test among 1,700 participants in the United States, including healthy participants, lung cancer patients, and other cancers Patient

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.